Vice President, Chief Accounting Officer and Former Interim Principal Financial Officer · Syndax Pharmaceuticals Inc (SNDX)

Alexander Nolte

FY2022 is the first fiscal year CompBrief holds for Alexander Nolte as a named executive officer of Syndax Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$760,864

Salary $338,000Stock awards $0

7th of 7 named executive officers at Syndax Pharmaceuticals by FY2022 total.

7 named officers on file for Syndax Pharmaceuticals, FY2022

Alexander Nolte’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • SNDX’s disclosed peer group of 22 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Syndax Pharmaceuticals’s whole pay program stands against its peers

  • Syndax Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SNDX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 7, 2023 (DEF 14A).

Free

Get Alexander Nolte’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Alexander Nolte compensation by year

Syndax Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Syndax Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022
Salary$338,000
Bonus$0
Stock awards$0
Option awards$323,364
Non-equity incentive$91,500
Pension and deferred compensation$0
All other$8,000
Total$760,864

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Syndax Pharmaceuticals Inc DEF 14A filed April 7, 2023, accession 0000950170-23-012189, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Syndax Pharmaceuticals Inc filed document, accession 0000950170-23-012189. Every figure is read from that document and cited to the page and table it appears in. Filed April 7, 2023.

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
Option32,292—$21.36
Option4,875—$9.47
Option23,125—$15.79
Option23,333—$19.36
Option1,667—$18.03
Option875—$9.00
Option375—$6.38

Per the Outstanding Equity Awards at Fiscal Year-End table in Syndax Pharmaceuticals Inc's FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Syndax Pharmaceuticals’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Michael MetzgerChief Executive Officer$4,113,476
Steve SabusChief Commercial Officer$3,916,050
Keith GoldanChief Financial Officer$2,992,538
Catherine MadiganChief Medical Officer$2,643,914
Briggs MorrisonPresident, Head of Research and Development and Former Chief Executive Officer$2,374,171
Luke AlbrechtGeneral Counsel and Secretary$1,468,073
Alexander Nolte · this pageVice President, Chief Accounting Officer and Former Interim Principal Financial Officer$760,864

The full Syndax Pharmaceuticals compensation record

free company brief

This page is one person within Syndax Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Syndax Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Syndax Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Alexander Nolte's compensation dossier · One-time report. No refunds.